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*A report on the ‘First Annual International 
Conference on Translational Research for Can-
cer and Other Disea es’ held at the Centre for 
Cellular and Molecular Biology, Hyderabad 
during 19–20 March 2005. 
pressive forces developed during mining 
activities. This was followed by a lecture 
by S. K. Chaulya (CMRI) on ‘Approaches 
for solving groundwater problems at 
Khadsaliya lignite mine, Bhavnagar district, 
Gujarat’. The next talk was by Tiwary, 
who focused on the fact that Sukinda ul-
tramafic belt of Orissa processes the 
largest chromite deposit of India associ-
ated with vast resources of oxide nickel 
ore and produces nearly 8% of chromite 
ore. It may be damaging nearby land and 
water resources. Using MODPATH, Tiwary 
showed that the movement of particles 
(pollutants) was found to be negligibly 
small (  10 m) over a period of 20 years 
in the first layer and 15 m over a period 
of 20 years in the second layer. N. C. 
Mondal (NGRI, Hyderabad) gave a lec-
ture on ‘Applications of MODFLOW in 
the study of groundwater flow and solute 
transport’ and also demonstrated Visual 
Modflow 2.6.1 taking a specific problem. 
According to Mondal, groundwater mod-
elli g depends upon conceptualization of 
the system. Gupta discussed about the 
groundwater problems in deep under-
ground gold mines in South Africa. In the 
last lecture, Gupta dealt with a spectrum 
of errors categorized into source, kind 
and nature during handling of groundwater 
data for mining areas.  
N. C. Mondal, National Geophysical 
Research Institute, Hyderabad 500 007, 
India. e-mail: ncmngri@yahoo.co.in 
B2B-2K5: The new buzz in translational research* 
Translational research is simply research 
that results in the development of new and 
improved medical treatments. The theme 
that discoveries made at the laboratory 
bench can lead to the delivery of more 
effective care at the hospital bedside, was 
captured in the catchy and alliterative sub-
title ‘B2B-2K5’ during the recently held 
conference. This report is a brief over-
view of the 30 talks delivered at this con-
ference by some of the leading clinicians 
and scientists from India and the United 
States.  
Imaging technologies leave magical 
impressions, as anybody who has had an 
X-ray, ultrasound, CT or PET scan can 
attest. Jason A. Koutcher (Memorial Sloan-
Kettering Cancer Center, New York City) 
described the recent progress made in 
applications of magnetic resonance imag-
ing (MRI) and magnetic resonance spec-
troscopic imaging (MRSI). MRI can now 
be used to scan the whole mouse and detect 
the presence of hepatic tumours. Three-
dimensional 31P-MRSI can be used to de-
tect the levels of individual metabolites 
(e.g. nucleotide triphosphates, phosphotidyl 
ethanolamine) in individual ‘voxels’ 
(volume pixels) of the liver. This allows 
one to determine when normal metabolism 
is restored following surgical resection 
of liver cancers. This is important for the 
administration of adjuvant chemotherapy. 
If chemotherapy is given too early it can 
lead to killing of the regenerating liver 
cells, but waiting too long post-surgery 
can allow the tumour to re-grow and the 
therapy would no longer be effective. 
MRSI can also be used to stage prostate 
cancers based on the levels of citrate and 
choline. Citrate levels are relatively high 
in the normal prostate, whereas high choline 
is an indication of rapidly proliferating 
tissues such as tumours. By measuring the 
levels of choline and citrate in individual 
voxels, one can localize where a tumour 
might be located in the prostate. This would 
allow biopsy to be directed to that loca-
tion, rather than taking a random biopsy 
sample. About 130 patients examined in 
this way, who subsequently underwent radi-
c l prostatomy, revealed that MRSI had a 
sensitivity of 85–90% for high-grade tu-
mours. The sensitivity was not as good 
for lower grade tumours. The approach is 
not without pitfalls. For example, spectral 
degeneration is seen in the region of 
haemorrhage and conditions like prostitis 
can cause false positives. 
Irradiated tumours can serve as a source 
of tumour-associated antigens. Alan Alfieri 
(Albert Einstein College of Medicine, 
New York City) described the exciting 
po sibilities of radiation-induced autolo-
gous tumour vaccination. Local tumour 
radiotherapy (60 Gy) was combined with 
injection of the cytokine Flt3-ligand (Flt3L) 
in a murine model of Lewis lung carci-
noma. Dendritic cells (DCs) are known 
to present antigen from apoptotic cells, 
and Flt3L is known to expand DCs in 
vivo and thus was expected to improve
antigen presentation from dying, irradiated 
tumour cells. Alfieri t al., found that radio-
therapy + Flt3L reduced pulmonary meta-
stases and significantly improved survival 
in C57Bl/6 mice with established footpad 
tumours. Mice treated with Flt3L a one 
showed delayed tumour growth, but eventu-
ally succumbed to tumour progression. 
The combination therapy of radiotherapy + 
Flt3L failed to work in immunodeficient 
athymic (nude) mice, implicating the role 
of T-cells in prolonging survival. Thus 
sequ ntial radiation and immunotherapy 
with Flt3L to enhance tumour antigen 
presentation may produce therapeutic re-
sponses against disseminated cancer and 
improvement in survival. Immunotherapy 
was also the theme of the talk by Ashok 
Khar (Centre for Cellular and Molecular 
Biology (CCMB), Hyderabad). He descri-
bed studies on the spontaneous regression 
of a rat histiocytoma transplanted sub-
cutaneously in a syngenic host. The major 
effector of this regression was the NK 
cell, which induced tumour antibody-depen-
dent tumour cell death via necrosis and 
apoptosis. His studies showed that immune 
cells (NK cells, dendritic cells and macro-
phag s) influx into the peritoneum. The 
NK cells get activated and then migrate 
back to the tumour to cause cell death.  
Radiation also holds promise for facilitat-
ing recovery from spinal cord injury in a 
rat model. Kalderon and Alfieri had pre-
viously demonstrated the beneficial effects 
of X-rays after transection injury to the 
nervous tissue. They had found that ra-
diation focused on the injury site pre-
v nted the degenerative process called 
cavitation and thus preserved structural 
integrity and electrophysiological func-
tion. Chitti R. Moorthy et al. (New York 
Medical College, Valhalla) did similar 
investigations, but with a contusion (crush) 
injury to the rat spinal cord and found 
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that they could achieve improved loco-
motor function if the radiation was delivered 
early enough. Moorthy also gave two 
other talks; one, a historical perspective 
on cancer research and another where he 
overviewed recent developments in radiation 
therapy. Among them are the use of a robot 
in brachytherapy, which would spare 
medical personnel from accidental expo-
sure. Another was the 4–6 fold enhancement 
of chemosensitivity of cancer cells when 
heated to 43°C. Richard J. Zeman (New 
York Medical College) described other 
approaches to enhance the recovery of 
locomotor function in the rat model of 
spinal cord injury. Ordinarily, injury 
causes inflammation, which increases the 
reactive oxygen species (ROS) and results 
in increased cell death, tissue loss and 
formation of a glial scar and, ultimately 
paralysis. Scavenging the ROS using either 
Tempol, a free-radical scavenger and anti-
oxidant that is already used as a radio-
protective agent to prevent radiation-
induced hair loss, or Clenbuterol, a beta 
2-agonist and anti-inflammatory agent 
resulted in more of the spinal tissue to be 
spared and in substantial recovery of loco-
motor function at the most severe levels 
of injury. These drugs were effective in a 
relatively prolonged therapeutic window. 
Similar results were seen in rats exposed 
to hyperbaric oxygen. 
 Moving up from the spinal cord, two 
talks described investigations with astro-
cytomas and gliomas. Malignant astrocyto-
mas are among the most resistant tumours 
to curative treatments. Mean survival 
without treatment is measured in weeks, 
and even with treatment, the mean sur-
vival is <1 year. Astrocytomas also show 
extreme heterogeneity within any given 
tumour. Several oncogenes (growth factors, 
growth factor receptors, kinases, tran-
scription factors, etc.) and tumour suppres-
sor genes have been identified as important 
in astrocytoma initiation and progression. 
Interestingly, protein kinase C (PKC) 
appears to be over-expressed in the early 
stages of astocytomas and then the tumour 
cells lose PKC activity as they progress 
to higher grades. Deborah L. Benzil (New 
York Medical College) described studies 
to determine whether the inhibition of 
PKC by Tamoxifen (an anti-estrogen at 
low doses, but a PKC inhibitor at a high 
doses), retarded progression of low-grade 
astrocytomas to a higher grade. Encour-
agingly, 30% of the patients showed good 
response to this treatment. She also re-
ported studies investigating the effects of 
anti angiogenesis agents, including tha-
lidomide. Transferrin is being used for tar-
getted chemotherapy (transmid). Gliomas 
also are difficult to access, display hete-
rogeneity, respond poorly to radio- and 
chemotherapy and have variable prognosis. 
Ravi Sirdeshmukh et al. (CCMB) ana-
lys d more than 3000 proteins from 30 
tumours using a 2DE/MS proteomics ap-
proach, to identify about 850 proteins that 
appeared to be differentially expressed 
b tween the tumour and control tissues. 
They found the molecular chaperone HSP 
70 to be down-regulated in many tumours. 
He suggested that this may correlate with 
destabilization of the cytoskeleton. Con-
sistent with this idea, they found that 
glial fibrillary acidic protein (GFAP), an 
intermediate filament protein, showed 
berrant phosphorylation at threonine 
and enhanced proteolysis in malignant 
cells. They observed distinct proteolytic 
forms of GFAP, which suggested that the 
pr tein underwent a regulated proteolysis. 
Thus GFAP proteolysis may serve to grade 
astrocytomas. Other differentially expressed 
prot ins include the tumour suppressor 
protein prohibitin, and Rho-GDP disso-
ciation inhibitor (Rho-GDI), a regulator 
of Rho proteins involved in cell growth 
regulation. It would be of interest to test 
wh ther the different molecular patterns 
observed in different tumours correlate 
with their clinicopathological differences. 
 Hepatocellular carcinoma (HCC) is the 
fifth most common cancer worldwide. 
HCC isk is increased 100-fold in people 
with Hepatitis B viral infection and up to 
900-fold in cirrhosis patients. The talk by 
Marcelo Facciuto (Westchester Medical 
Center and New York Medical College) 
described the criteria for eligibility for an 
orthologous liver transplant as well as 
several ways to control tumour growth 
du ing the wait for suitable donor tissue. 
These include ethanol injection and 
chemo-embolization of the arteries and liv-
ing donor liver transplant. In living donor 
transplantation, it becomes imperative to 
optimize graft/host sizes to avoid ‘small 
for size’ syndrome (if the graft is too 
small) and graft versus host disease (if 
the graft is too large). Hepatocyte trans-
plantation can ameliorate radiation-indu-
ced liver damage. Alfieri described studies 
in which rats were subjected to heavy ir-
radiation of the liver, after which tagged 
autologous hepatocytes were introduced 
and were found to be capable of restoring 
full liver functionality. This work sug-
gests that autologous transplantation of 
tagged hepatocytes sorted by magnetic 
cell separation or flow cytometry may be 
useful for patients with diffuse liver dis-
eas . In yet another talk, Alfieri described 
more applications of flow cytometry and 
laser scanning cytometry in cancer res-
e rch. In particular, evaluating the extent 
of apoptosis on the basis of peaks indi-
c ting sub-G1 DNA content and dUTP-
FITC incorporation to directly view DNA 
breaks. These tools have been used to 
monitor the effectiveness of chemotherapy 
in leukaemia. 
 Many cancers result from the formation 
of tumour-specific chromosomal changes, 
specifically translocations. Moreover the 
translocation breakpoints often correlate 
with the location of oncogenes. Suresh 
Jhanwar (Memorial Sloan-Kettering Can-
cer Center) gave several examples of 
cancer-associated chromosome aberra-
tions that were instrumental in the identi-
fication of cancer genes. For example, 
chronic myelogenous leukaemia (CML) 
is caused by a translocation that leads to 
the formation of a consitutively active 
gene for a tyrosine kinase fusion protein 
called Bcr-Abl, which affects the cell 
signalling pathway. Acute promyelocytic 
leukaemia is due to translocation of the 
retinoic acid receptor with a novel gene 
PML, resulting in the inhibition of dif-
ferentiation at the promyelocytic stage. 
Somatic mutations in many of the cancer 
genes identified in this way, are found to 
be responsible for sporadic cases of these 
cancers. For example, familial renal cell 
carcinoma (RCC) is seen in families seg-
regating the translocation T(3; 8) (p14; 
q24). It was found that all the cancer 
c lls had lost the derived chromosome 8 
(der 8), which suggested that the cancer 
was caused by loss of heterozygosity for 
a locus on chromosome 3, in the region 
distal to the translocation breakpoint. When 
normal cells from patients with familial 
RCC were transfected with Ha-ras, cells 
sh wing the transformed phenotype had 
lost the gene in chromosome 3 that was 
later identified to be VHL, the gene for 
v n Hippel–Lindau syndrome. The VHL 
gene is mutated in many sporadic cases 
of RCC. Levy Kopelovich (National Cancer 
I stitute, Bethesda) described studies by 
his group on clinically normal cells from 
persons with conditions that impart a 
dominantly heritable risk for cancer (e.g. 
mutant tumour suppressor gene). They 
detected ‘one-hit’ RNA expression pro-
files, including aberrations of the clini-
cally normal cells in a gene-specific manner, 
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in heterozygous individuals. Examples 
are microarray cluster analysis of different 
forms of renal cancer carcinoma caused 
by mutations in TSC2 (tuberous sclerosis 
2) versus VHL (von Hippel–Lindau syn-
drome), and TP53 (Li-Fraumeni syndrome). 
This has significance to the discovery of 
cancer preventive agents. They also looked 
at highly malignant cells in fluctuation 
studies to isolate clones with different 
phenotypes. The clones are being studied 
for their response to chemopreventive 
agents. Stably normal clones are tagged 
with GFP/RFP, orthotopically implanted 
in recipient mice and their progression in 
the absence and presence of chemopre-
ventive agents is monitored in real time. 
This may result in the discovery of chemo-
preventive agents. 
 E. Premkumar Reddy (Temple University 
School of Medicine) delivered the Gold 
Medal Address. He described recent 
studies on PLK-1 (polo-like kinase 1), a 
serine/threonine protein kinase that plays 
a regulatory role in microtubule assembly. 
During mitotic spindle assembly PLK-1 
associates with the centrosomes, probably 
affecting tubulin polymerization, and is 
found in the mid-zone during telophase. 
Mutations in the Drosophila PLK-1 
homologue showed blockage at different 
steps in mitosis. Overexpression of PLK-
1 in NIH 3T3 cells was shown to result 
in a transformed phenotype and PLK-1 
was also found to be over-expressed in 
many human tumours. Esophageal cancer 
patients with high levels of PLK-1 ex-
pression had a significantly poorer prog-
nosis than patients with low expression. 
Antisense oligonucleotides and siRNA 
directed against the PLK-1 mRNA in-
duced mitotic defects which led to apoptosis. 
All these results suggested that PLK-1 
acted as an oncogene. Knockdown of PLK-1 
results in mitotic arrest, spindle abnor-
malities and apoptosis. ON 01910 is a 
small molecule kinase inhibitor with potent 
activity against PLK-1 in assays that 
used CDC25c or casein as substrate. ON 
01910 was found to compete for the sub-
strate-binding pocket of PLK-1 and the 
inhibition was irreversible. Normal cells 
treated with ON 01910 did not undergo 
apoptosis, presumably because the presence 
of a checkpoint arrested them in G1. 
Treatment of a broad spectrum of human 
tumour cells, including those that are 
multi-drug resistant, with ON 01910 
causes spindle and centrosome abnor-
malities that led to apoptosis. Inhibition 
and regression of tumour growth by ON 
01910 was also seen in xenograft models 
of human cancers such as hepatic, pan-
creatic, colon and breast tumours and in 
lymphoma. ON 01910 caused complete 
remission when used in combination 
th rapy with adriamycin. Indeed, it appeared 
to counter the weight loss seen with the 
use of adriamycin. This suggests that 
drugs that promote G1 arrest will overcome 
the toxic side effects of chemotherapy. 
ON 01910 also blocked other kinases such 
as Flt-1 and Met, and thus could be effective 
against tumour invasiveness and angio-
genesis. It has been approved by the US 
FDA in phase-I clinical trials. 
 G eta K. Vemuganti et al. (L. V. Prasad 
Eye Institute, Hyderabad) are developing 
cell-therapy approaches for the treatment 
of corneal diseases. She described the re-
constitution of the corneal epithelium on 
an amniotic membrane support by co-cul-
turing segments excised from the limbal 
region of the cornea of an unaffected eye 
together with conjunctival cells, using a 
small ring to separate the two cell types. 
The resulting cell mono-layer could then 
be used for transplantation and recon-
struction of the ocular surface. Among 
250 patients treated in this way, the suc-
cess rate was 70%. Vemuganti et al. are 
also exploring the trans-differentiation of 
adult bone marrow stromal cells into retinal 
ce ls. Vijay Anand P. Reddy (Apollo 
Cancer Hospital, Hyderabad) described 
the treatment of introcular tumours (retino-
blastoma and melanoma). His group uses 
ruthenium (Ru-109) radioactive plaques 
to deliver a high dose of radiation to a 
tumour and a negligible dose to the sur-
rounding tissue. Brachytherapy is the 
procedure in which the radiation source 
is implanted onto the tumour. The success 
rate for his group was 16/17 eyes.  
 Clinical trials are essential to address 
questions of efficacy and toxicity of cancer 
therapies. D. Raghunadharao (Nizam’s 
Institute of Medical Sciences, Hyderabad) 
discussed the conduct of clinical trials as 
attempts to answer scientific questions, 
while adhering to the principles of law, 
morals and ethics to protect the partici-
pants of such trials. He highlighted the 
p oblems arising from the general lack of 
awareness of both the scientific and ethical 
principles in India. S. H. Advani (Raheja 
Hospital, Mumbai) described the impres-
sive gains in survival achieved by moving 
anti-cancer therapy from targetting DNA 
replication in dividing cells to interfering 
w th a specific molecular target, usually 
a protein, that has a critical role in tumour 
growth or progression. Imatinib mesylate 
( hosphorylation blocker from Novartis) 
which targets tyrosine kinase and is used 
to reat CML and metastatic gastrointesti-
nal stromal tumours, was a prime example. 
HER2/neu inhibitors like geftinib and 
trastuzumab are used to target tyrosine 
kin se receptors like EGFR and used in 
the treatment of breast cancers. Thalido-
mide blocks the interaction of plasma 
cells with bone marrow stromal cells, 
wh ch causes bone resorption in multiple 
myeloma. Angiogenesis inhibitors like 
bevacizumab target VEGF and are used 
in metastatic colon cancer, and mono-
clonal antibodies like rituximab, an anti-
CD20 antibody, are approved for B-cell 
non-Hodgkin’s lymphoma. Thus by un-
d rstanding the molecular changes that 
underlie cancer development, the mal-
functioning molecules and pathways can 
be targetted to achieve more effective 
and rational therapy. Purvish M. Parikh 
(Tata Memorial Hospital, Mumbai) dis-
cussed the clinical use of imatinib to 
neutralize the tyrosine kinase activity, of 
the bcr-abl protein in CML, which heralded 
the era of targetted therapy. However, 
this drug caused dermatological side effects, 
and also resulted in myelosuppression, 
a d imatinib resistance correlated with 
specific mutations in tumour cells. Real 
time PCR revealed that residual molecular 
disease persisted in patients treated with 
imatinib alone. Another example of dosage 
and schedule modification studies was 
gemcitabine, a pro-drug that needs to be 
activated in the body by deoxycytidine 
kinase. This enzyme gets saturated in 
30 min. Therefore, the effect of prolong-
ing the infusion time rather than increas-
ing the dose of the drug was examined. 
This also results in the saving of as much 
as 66% of the cost of treatment.  
 S veral talks described studies of a 
relatively more basic kind. Meena Jhan-
w r-Uniyal (New York Medical College) 
described a microarray-based study to 
unravel the genetic basis of cancer meta-
stasis. In various malignancies, metastasis 
is inversely related to the abundance of 
nm23 protein expression. Jhanwar-Uniyal 
et al. used cDNA microarrays to identify 
novel genes and functional pathways in 
nm23-mediated spontaneous breast meta-
sta is. The experiments were performed 
in a pair of cell lines derived from human 
mammary carcinoma cell line MDA-MB-
435, namely C-100 (only vector trans-
fected; highly metastatic) and H1-177 
(nm23 transfected; low metastatic). They 
NEWS 
 
CURRENT SCIENCE, VOL. 88, NO. 11, 10 JUNE 2005 1726 
found significant and consistent alterations 
in the expression (up- and down-regula-
tion) of 2158 genes in a total of almost 
20,000 genes between the high and low 
metastatic cells. The results suggest that 
the mechanism of action of metastasis 
suppression may involve nm23-induced 
down-regulation of genes associated with 
cell adhesion, motility (e.g. integrins al-
pha2, -8, -9, -L and -V, collagen type VIII 
alpha1, fibronectin 1, catenin, TGF-beta2, 
FGF7, MMP14 and 16, ErbB2) and certain 
tumour/metastasis suppressors (two mem-
bers of SWI/SNF-related matrix-associa-
ted proteins 2 and 5 and PTEN). They also 
found that metastatic cells showed a 
greater expression of Rho, which would 
predict that inhibition of Rho, say by 
NFkB, might reduce the metastatic potential 
of cancer cells. Moni Abraham Kuriakose 
(Amrita Institute of Medical Science, 
Kochi) described a microarray-based pro-
filing of tumour-specific gene expression 
that was done to recognize genes that 
might identify novel therapeutic targets 
in head and neck squamous cell carcinomas 
(HNSCCA) and oral cancers. HNSCCA 
tumour tissue and normal mucosal tissue 
were harvested at the time of surgery 
from patients with histologically confirmed 
HNSCCAs and cDNA libraries were con-
structed from the paired surgical speci-
mens. Biotinylated RNA was transcribed 
from the cDNA library and hybridized to 
high-density microarrays containing ap-
proximately 12,000 human genes. Altered 
gene expression of HNSCCAs was iden-
tified by comparison to corresponding 
normal mucosal tissues and subjected to 
hierarchical clustering of data. Analysis 
revealed that the gene expression profiles 
could distinguish the tumours from non-
malignant tissues. Reproducible gene ex-
pression changes were observed in 227 
genes representing previously identified 
chemokines, tumour suppressors, differ-
entiation markers, matrix molecules, 
membrane receptors, and transcription 
factors that correlated with neoplasia, in-
cluding 46 previously uncharacterized 
enes. Significant expression of a collagen 
gene and a novel gene was reproducibly 
observed in the tumours, whereas these 
genes were virtually undetectable in their 
corresponding adjacent nonmalignant tis-
su s. Kuriakose et al. now aim at combining 
gene chip technology with bioinformatics 
to develop a database of molecular taxo-
nomy of the tumour. This could identify 
sensitive molecular markers for early tu-
mour detection, prognosis, and novel tar-
gets for interceptive therapeutics.  
 Gopal C. Kundu (National Centre for 
Cell Science, Pune) spoke on Osteopontin 
(OPN), a chemokine-like extracellular 
matrix (ECM) protein that appears to induce 
degradation of the ECM in breast cancer 
and melanoma models by regulating cell 
motility, invasiveness and tumour growth. 
OPN was shown to regulate NFkB-medi-
ated activation of pro-MMP-2, a promatrix 
metalloproteinase. OPN does this by sti-
mul ting IkB phosphorylation and deg-
adation and this step can be inhibited by 
curcumin and might account for curcu-
min-induced regression of a transplanted 
melanoma. OPN also enhances the levels 
of nuclear factor inducing kinase (NIK) 
that results in the increased activity of 
urokinase-type plasminogen activator, a 
widely acting serine protease that degrades 
the ECM. In breast cancer cells, OPN was 
sh wn to activate PI-3 kinase and MAPK 
signalling pathways. These effects of OPN 
underlie its regulation of cell motility 
a d invasiveness. According to Kumaravel 
Somasundaram (Indian Institute of Sci-
nce, Bangalore), many cancers, in parti-
cular ~75% of invasive breast cancers, 
use epigenetic means (e.g. cytosine methy-
lation) to turn-off expression of the tran-
scription factor activator protein-2 alpha 
(AP-2a), which functions as a tumour 
suppressing pro-apoptotic factor. This 
causes cancerous cells to become insensitive 
to chemotherapeutic drugs that act via 
the induction of apoptosis. Treatment of 
such cancer cells with 5AzaC turns on 
AP-2a and restores the cancer cells to che-
mosensitivity. 
 Other highlights of the meeting were 
an inaugural session in which N. K. 
Ganguly (Indian Council of Medical Re-
search, New Delhi) spoke on some of the 
challenges that confront medical research 
in India. For example, India has 600 dis-
tricts but only about 20 field epidemio-
logists. Diagnostic kits developed by 
Indian scientists are not being used for 
any of the following reasons; they are not 
cost-effective, or they are not heat-stable, 
or they cannot be handled in the rural areas. 
Although in principle, the incidence of 
cervical cancer can be brought down by 
therapeutic vaccination against human 
papilloma virus or by on-site colposcopy 
and cryosurgery, sociological factors make 
it difficult to do so in a village. We are 
also weak in clinical trials and have never 
done trials on new entities. We need to 
have a research/policy interface. We lack 
the infrastructure to say, test GM foods, 
or answer questions such as ‘what is the 
burden of cardiovascular disease in Kar-
nataka?’. On the other hand, Lalji Singh 
(CCMB) pointed out the opportunities of-
fered to basic and clinical scientists by the 
vast and diverse Indian population. Singh 
also touched upon the revolution in genet-
ics that is going to transform clinical prac-
tice, particularly for diseases that run in 
families, but do not follow Mendelian 
rules.  
 This meeting was attended by about 
400 participants, 57 of whom presented 
their work as posters. For more informa-
tion on this and future meetings, contact 
ushaks@ccmb.res.in, vradha@ccmb.res. 
in or moorthycr@yahoo.com  
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